Inovio Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.4501
- Today's High:
- $0.4649
- Open Price:
- $0.46
- 52W Low:
- $0.38
- 52W High:
- $2.61
- Prev. Close:
- $0.46
- Volume:
- 1242592
Company Statistics
- Market Cap.:
- $122.78 million
- Book Value:
- 0.632
- Revenue TTM:
- $9.62 million
- Operating Margin TTM:
- -1795.24%
- Gross Profit TTM:
- $-177388235
- Profit Margin:
- 0%
- Return on Assets TTM:
- -31.18%
- Return on Equity TTM:
- -72.13%
Company Profile
Inovio Pharmaceuticals Inc had its IPO on 1998-02-12 under the ticker symbol INO.
The company operates in the Healthcare sector and Biotechnology industry. Inovio Pharmaceuticals Inc has a staff strength of 135 employees.
Stock update
Shares of Inovio Pharmaceuticals Inc opened at $0.46 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.45 - $0.46, and closed at $0.45.
This is a -1.74% slip from the previous day's closing price.
A total volume of 1,242,592 shares were traded at the close of the day’s session.
In the last one week, shares of Inovio Pharmaceuticals Inc have increased by +0.44%.
Inovio Pharmaceuticals Inc's Key Ratios
Inovio Pharmaceuticals Inc has a market cap of $122.78 million, indicating a price to book ratio of 1.7213 and a price to sales ratio of 40.0029.
In the last 12-months Inovio Pharmaceuticals Inc’s revenue was $9.62 million with a gross profit of $-177388235 and an EBITDA of $-169114496. The EBITDA ratio measures Inovio Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Inovio Pharmaceuticals Inc’s operating margin was -1795.24% while its return on assets stood at -31.18% with a return of equity of -72.13%.
In Q2, Inovio Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 71.2%.
Inovio Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.63 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Inovio Pharmaceuticals Inc’s profitability.
Inovio Pharmaceuticals Inc stock is trading at a EV to sales ratio of 19.096 and a EV to EBITDA ratio of -0.6486. Its price to sales ratio in the trailing 12-months stood at 40.0029.
Inovio Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $233.04 million
- Total Liabilities
- $51.93 million
- Operating Cash Flow
- $53.91 million
- Capital Expenditure
- $23915
- Dividend Payout Ratio
- 0%
Inovio Pharmaceuticals Inc ended 2024 with $233.04 million in total assets and $0 in total liabilities. Its intangible assets were valued at $233.04 million while shareholder equity stood at $169.37 million.
Inovio Pharmaceuticals Inc ended 2024 with $32046.00 in deferred long-term liabilities, $51.93 million in other current liabilities, 268072.00 in common stock, $-1564031634.00 in retained earnings and $10.51 million in goodwill. Its cash balance stood at $52.71 million and cash and short-term investments were $194.93 million. The company’s total short-term debt was $19,059,778 while long-term debt stood at $0.
Inovio Pharmaceuticals Inc’s total current assets stands at $203.28 million while long-term investments were $2.78 million and short-term investments were $142.21 million. Its net receivables were $5.12 million compared to accounts payable of $10.36 million and inventory worth $3.23 million.
In 2024, Inovio Pharmaceuticals Inc's operating cash flow was $53.91 million while its capital expenditure stood at $23915.
Comparatively, Inovio Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.45
- 52-Week High
- $2.61
- 52-Week Low
- $0.38
- Analyst Target Price
- $1.33
Inovio Pharmaceuticals Inc stock is currently trading at $0.45 per share. It touched a 52-week high of $2.61 and a 52-week low of $2.61. Analysts tracking the stock have a 12-month average target price of $1.33.
Its 50-day moving average was $0.48 and 200-day moving average was $1 The short ratio stood at 7.61 indicating a short percent outstanding of 0%.
Around 163.8% of the company’s stock are held by insiders while 3657.2% are held by institutions.
Frequently Asked Questions About Inovio Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia, including cervical, vulvar, and anal dysplasia and is under phase II/III clinical trials; INO-3107 for HPV-related recurrent respiratory rapillomatosis and is under Phase 1/2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under phase 1b trial; and INO-4500 vaccine for lassa fever, which is under phase 1b trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.